Avalo Therapeutics Inc Asset Resilience Ratio
Avalo Therapeutics Inc asset resilience ratio. Avalo Therapeutics Inc (AVTX) has an Asset Resilience Ratio of 67.67% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Avalo Therapeutics Inc (AVTX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Avalo Therapeutics Inc (2019–2020)
Asset resilience ratio of Avalo Therapeutics Inc from 2019 to 2020. This chart shows how Avalo Therapeutics Inc's Asset Resilience Ratio has changed over time. Read AVTX liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Avalo Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AVTX total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $84.65 Million | 67.67% |
| Total Liquid Assets | $84.65 Million | 67.67% |
Asset Resilience Insights
- Very High Liquidity: Avalo Therapeutics Inc maintains exceptional liquid asset reserves at 67.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Avalo Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Avalo Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Avalo Therapeutics Inc Asset Resilience Ratio by Year (2019–2020)
Avalo Therapeutics Inc asset resilience ratio by year from 2019 to 2020. The table below shows the annual Asset Resilience Ratio data for Avalo Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.00% | $0.00 | $43.76 Million | -- |
| 2019-12-31 | 21.13% | $7.63 Million | $36.11 Million | -- |
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more